GE HealthCare unveils head-only MRI scanner for advanced neuroscience research

GE Healthcare has introduced SIGNA MAGNUS, a groundbreaking head-only magnetic resonance imaging (MRI) scanner, signalling a significant advancement in neuroscience research. This technology, pending FDA 510(k) clearance, holds immense promise in expanding the horizons of neuroscience, a field previously constrained by the limitations of conventional whole-body MRI systems.

Neurological disorders, affecting a substantial 43% of the global population, present a formidable challenge, with current MRI capabilities only able to diagnose a fraction of these conditions. SIGNA MAGNUS promises to address this gap by providing researchers with a powerful tool to explore the intricacies of the brain with unprecedented precision.

Tailored specifically for neurological and oncological research, SIGNA MAGNUS boasts cutting-edge features including superior gradient performance with HyperG gradient technology, advanced imaging techniques, and the potential to unveil new biomarkers crucial for the diagnosis and treatment of complex brain diseases. Its exceptional diffusion performance, facilitated by innovative gradient design, offers researchers a deeper understanding of neural architecture.

Moreover, the cost-effective upgrade path provided by GE Healthcare allows many existing 3.0T systems to be upgraded to SIGNA MAGNUS, minimising capital expenditure for research institutions. This innovation opens new avenues for neuroscientific breakthroughs, promising to revolutionise our understanding and treatment of neurological disorders.

Click here to read the original news story.